Sichuan Biokin Pharmaceutical (SHA:688506) received approval from China's National Medical Products Administration for the clinical trial of a combination therapy with iza-bren for injection (BL-B01D1), according to a Shanghai bourse filing on Wednesday.
The drug will be tested in combination with small-molecule targeted therapies for the treatment of non-small cell lung cancer.